dr. raje discusses the impact of bb2121in myeloma
Published 5 years ago • 314 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:55
dr. raje discusses the tolerability of bb2121 in myeloma
-
1:38
dr. raje on bb21217 in multiple myeloma
-
13:23
dr. raje discusses investigational treatment strategies in multiple myeloma
-
1:23
dr. raje on quadruplet regimens in myeloma
-
1:52
dr. raje on the effectiveness of quadruplet therapies in multiple myeloma
-
0:52
dr. raje on future research with bites in multiple myeloma
-
1:00
dr. raje on remaining questions in multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:43
dr. raje on key challenges faced in multiple myeloma
-
1:21
noopur raje on bb21217 in myeloma
-
1:38
dr. raje on treatment approaches for relapsed/refractory myeloma
-
0:21
copy of dr. raje on bb21217 in multiple myeloma
-
1:17
dr. raje on the design of the endurance trial in newly diagnosed multiple myeloma
-
1:41
dr. raje on the efficacy of belantamab mafodotin in multiple myeloma
-
0:53
dr. raje on the potential utility of belantamab mafodotin in multiple myeloma
-
2:11
dr. raje highlights treatment options for relapsed multiple myeloma
-
0:55
dr. raje compares data for triplet regimens in myeloma
-
5:24
dr. noopur raje discusses kidney disease in multiple myeloma
-
4:57
impact of genomics on multiple myeloma treatment selection, with dr. noopur raje